© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg-Eppendorf, D-20246 Hamburg, Germany
boeger{at}uke.uni-hamburg.de
* Arbeitsgruppe Klinische Pharmakologie, Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. Tel.: +49-40-42803-9759; fax: +49-40-42803-9757.
There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of the major endothelium-derived vasoactive mediators is nitric oxide (NO). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions (i.e., 3–15 µmol/l); ADMA also causes local vasoconstriction when it is infused intraarterially. The biochemical and physiological pathways related to ADMA are now well understood: dimethylarginines are the result of the degradation of methylated proteins; the methyl group is derived from S-adenosylmethionine. Both ADMA and its regioisomer, SDMA, are eliminated from the body by renal excretion, whereas only ADMA, but not SDMA, is metabolized via hydrolytic degradation to citrulline and dimethylamine by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). DDAH activity and/or expression may therefore contribute to the pathogenesis of endothelial dysfunction in various diseases. ADMA is increased in the plasma of humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, and chronic heart failure. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilation. In several prospective and cross-sectional studies, ADMA evolved as a marker of cardiovascular risk. With our increasing knowledge of the role of ADMA in the pathogenesis of cardiovascular disease, ADMA is becoming a goal for pharmacotherapeutic intervention. Among other treatments, the administration of L-arginine has been shown to improve endothelium-dependent vascular function in subjects with high ADMA levels.
KEYWORDS Endothelium; Nitric oxide; Coronary heart disease; Prognosis; Oxidative stress
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Aversa, R. Bruzziches, D. Francomano, M. Natali, and A. Lenzi Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Therapeutic Advances in Urology, October 1, 2009; 1(4): 179 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Li, A. Wilson, X. Gao, R. Kuruba, Y. Liu, S. Poloyac, B. Pitt, W. Xie, and S. Li Coordinated Regulation of Dimethylarginine Dimethylaminohydrolase-1 and Cationic Amino Acid Transporter-1 by Farnesoid X Receptor in Mouse Liver and Kidney and Its Implication in the Control of Blood Levels of Asymmetric Dimethylarginine J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 234 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. BLAISE, R. MAAS, C. TROCME, G. D. KOM, M. ROUSTIT, P. H. CARPENTIER, and J.-L. CRACOWSKI Correlation of Biomarkers of Endothelium Dysfunction and Matrix Remodeling in Patients with Systemic Sclerosis J Rheumatol, May 1, 2009; 36(5): 984 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Boger, L. M. Sullivan, E. Schwedhelm, T. J. Wang, R. Maas, E. J. Benjamin, F. Schulze, V. Xanthakis, R. A. Benndorf, and R. S. Vasan Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community Circulation, March 31, 2009; 119(12): 1592 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. King and M. DeLegge The Impact of Fiber Supplementation on ADMA Levels Nutr Clin Pract, February 1, 2009; 24(1): 80 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wells, M. C. Buford, C. T. Migliaccio, and A. Holian Elevated Asymmetric Dimethylarginine Alters Lung Function and Induces Collagen Deposition in Mice Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 179 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sud, S. M. Wells, S. Sharma, D. A. Wiseman, J. Wilham, and S. M. Black Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1407 - C1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Carlstrom, R. D. Brown, J. Edlund, J. Sallstrom, E. Larsson, T. Teerlink, F. Palm, N. Wahlin, and A. E. G. Persson Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals Am J Physiol Renal Physiol, February 1, 2008; 294(2): F362 - F370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Monsalve, P. J. Oviedo, M. A. Garcia-Perez, J. J. Tarin, A. Cano, and C. Hermenegildo Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells Cardiovasc Res, January 1, 2007; 73(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Louden, D. Brott, A. Katein, T. Kelly, S. Gould, H. Jones, G. Betton, J.-P. Valetin, and R. J. Richardson Biomarkers and Mechanisms of Drug-Induced Vascular Injury in Non-Rodents Toxicol Pathol, January 1, 2006; 34(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H Boger, J. P Cooke, and P. Vallance ADMA: an emerging cardiovascular risk factor Vascular Medicine, July 1, 2005; 10(1_suppl): S1 - S2. [PDF]
|
|
|
|
|
|
R. H Boger Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials Vascular Medicine, July 1, 2005; 10(1_suppl): S19 - S25. [Abstract] [PDF]
|
|
|
|
|
|
S. Dayal and S. R Lentz ADMA and hyperhomocysteinemia Vascular Medicine, July 1, 2005; 10(1_suppl): S27 - S33. [Abstract] [PDF]
|
|